Who Generates More Revenue? Eli Lilly and Company or Gilead Sciences, Inc.

Eli Lilly outpaces Gilead in revenue growth over a decade.

__timestamp	Eli Lilly and Company	Gilead Sciences, Inc.
Wednesday, January 1, 2014	19615600000	24890000000
Thursday, January 1, 2015	19958700000	32639000000
Friday, January 1, 2016	21222100000	30390000000
Sunday, January 1, 2017	22871300000	26107000000
Monday, January 1, 2018	21493300000	22127000000
Tuesday, January 1, 2019	22319500000	22449000000
Wednesday, January 1, 2020	24539800000	24689000000
Friday, January 1, 2021	28318400000	27305000000
Saturday, January 1, 2022	28541400000	27281000000
Sunday, January 1, 2023	34124100000	27116000000
Monday, January 1, 2024	45042700000	28754000000

Unveiling the hidden dimensions of data

Revenue Race: Eli Lilly vs. Gilead Sciences

In the competitive landscape of the pharmaceutical industry, revenue generation is a key indicator of a company's market strength and innovation prowess. Over the past decade, Eli Lilly and Company and Gilead Sciences, Inc. have been at the forefront of this race. From 2014 to 2023, Eli Lilly's revenue surged by approximately 74%, reaching its peak in 2023. In contrast, Gilead Sciences experienced a more modest growth, with a 9% increase over the same period.

A Decade of Growth

Eli Lilly's revenue growth was particularly notable in the last three years, with a 20% increase from 2021 to 2023. Meanwhile, Gilead Sciences saw a slight decline in revenue from 2021 to 2023, highlighting the dynamic shifts in the pharmaceutical sector. This data underscores the importance of strategic innovation and market adaptation in maintaining a competitive edge.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025